FDA Approves LEVOTHYROXINE SODIUM — Lannett Company, Inc

Lannett Company, Inc. leverages the regulatory milestone for its oral levothyroxine sodium formulation to secure a consistent market footprint in the generic thyroid hormone replacement sector, aiming to capitalize on high patient volume despite ongoing price-sensitivity pressures.